Key Points
- CFO Jean Franchi sold 353 shares at an average of $69.06 on Feb 25 for $24,378, a routine 0.49% reduction that leaves her with 70,990 shares valued at about $4.9M.
- Disc reported a slight EPS beat (Q4 EPS of ($1.62) vs. ($1.69) est.) but faces near‑term headwinds after the board approved a restructuring following an FDA response and an investor litigation probe, increasing execution and regulatory uncertainty.
- Large institutional buying lifted holdings by firms like RA Capital, Vanguard and JPMorgan, with institutions owning 83.7% of the stock and analysts holding a consensus "Moderate Buy" and average target of $102.
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) CFO Jean Franchi sold 353 shares of the firm's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $69.06, for a total value of $24,378.18. Following the completion of the sale, the chief financial officer directly owned 70,990 shares of the company's stock, valued at $4,902,569.40. The trade was a 0.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Disc Medicine Price Performance
Shares of NASDAQ IRON opened at $66.62 on Friday. The company's 50-day moving average is $74.43 and its 200 day moving average is $75.40. The company has a debt-to-equity ratio of 0.05, a current ratio of 23.45 and a quick ratio of 23.45. The stock has a market capitalization of $2.51 billion, a P/E ratio of -11.12 and a beta of 0.88. Disc Medicine, Inc. has a 1 year low of $30.82 and a 1 year high of $99.50.
Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.69) by $0.07. The firm had revenue of ($19.88) million during the quarter, compared to the consensus estimate of $0.15 million. On average, sell-side analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. grew its holdings in Disc Medicine by 25.3% during the 4th quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock valued at $156,925,000 after purchasing an additional 399,026 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Disc Medicine by 22.1% in the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock valued at $140,371,000 after acquiring an additional 319,621 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Disc Medicine by 28.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company's stock worth $134,839,000 after purchasing an additional 371,576 shares during the period. JPMorgan Chase & Co. boosted its position in Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company's stock valued at $125,557,000 after acquiring an additional 828,248 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in Disc Medicine by 7.7% during the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company's stock valued at $120,566,000 after purchasing an additional 108,197 shares in the last quarter. Institutional investors own 83.70% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on IRON. TD Cowen reiterated a "buy" rating on shares of Disc Medicine in a research note on Friday, December 19th. UBS Group reissued an "overweight" rating on shares of Disc Medicine in a report on Thursday, January 15th. Morgan Stanley set a $75.00 price objective on shares of Disc Medicine in a research report on Tuesday, February 17th. Cantor Fitzgerald reduced their target price on shares of Disc Medicine from $153.00 to $125.00 and set an "overweight" rating for the company in a report on Tuesday, February 17th. Finally, Truist Financial decreased their price target on Disc Medicine from $114.00 to $83.00 and set a "buy" rating on the stock in a report on Friday. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $102.00.
Check Out Our Latest Report on IRON
More Disc Medicine News
Here are the key news stories impacting Disc Medicine this week:
- Positive Sentiment: Beat on quarterly results — Disc reported Q4 and full‑year 2025 results with EPS of ($1.62), beating consensus (($1.69)) and provided a business update; the small earnings beat is a short‑term positive signal for execution and guidance clarity. Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
- Neutral Sentiment: Analyst target lowered but rating sustained — Truist cut its price target from $114 to $83 but kept a "buy" rating, signalling continued analyst confidence in the longer‑term thesis despite reduced near‑term expectations. Truist lowers price target to $83
- Neutral Sentiment: Insider sale by CFO — CFO Jean M. Franchi sold 353 shares at ~$69; the sale is small (0.49% reduction in her holdings) and appears routine rather than a clear signal of negative private information. CFO insider sale filing
- Neutral Sentiment: Short‑interest report is inconclusive — a MarketBeat entry shows anomalous/zero short interest data for February (days‑to‑cover 0.0), so there’s no clear short‑squeeze or elevated short pressure signal from this report.
- Negative Sentiment: Restructuring after FDA response — Disc’s board approved a restructuring following an FDA response, implying a regulatory/setback event that prompted corporate changes; this raises near‑term execution and timeline uncertainty for pipeline programs. Disc Medicine Implements Restructuring Following FDA Response
- Negative Sentiment: Investor litigation alert — Pomerantz LLP announced an investigation into Disc Medicine, which can increase legal risk, potential distraction, and perceived governance concerns among investors. Pomerantz investigates Disc Medicine
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
